About
Cabaletta Bio Inc (NASDAQ:CABA) — investor relations, events, news, and company updates on 6ix.
Latest News
Yesterday
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel
Yesterday
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel
Apr 27 2026
Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting
Apr 14 2026
First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform
Mar 23 2026
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Financials
Revenue
$0
Market Cap
$335.08 M
EPS
-2.10
Translate